• Store

APHON Webinar Program

APHON recognizes that not all nurses can spend time away from their work and families to attend the Annual Educational Conference and therefore has developed webinars to serve this population.  APHON webinars focus on single topic areas that have been identified by members as needing further study. 

APHON members may earn CNE at no cost, the fee for non-members is $15. Participants will be awarded 1 CNE contact hour upon completion of the hour-long webinar and completion of a post-test and evaluation. Attendance for the entire webinar session is required for CNE credit. A link to complete the evaluation form and claim CNE contact hours will be distributed after each webinar.

Upcoming Webinar Schedule

April

Parent-Child Communication and Testing for Cancer Predisposition

Date:Thursday, April 6, 2017
Time:1 pm Central Time

Presenter

Belinda Mandrell, PhD RN CPNP
Pediatric Nurse Practitioner
St. Jude Children's Research Hospital
Memphis, TN

Description

It is estimated that 20% of individuals with Li-Fraumeni syndrome (LFS) will be diagnosed with cancer before 20 years of age; however, it is not yet possible to determine when and in whom cancer will develop. Thus, there is life-long uncertainty associated with LFS and this uncertainty is the focus of much of the counseling and medical management of LFS patients. To increase understanding of the challenges inherent in the testing of children for an underlying cancer predisposing condition, we explored parent-child communication. This qualitative study interviewed 14 families with a LFS history who proceeded with genetic testing of their child/children. This presentation will describe the factors that influence when parents decide to initiate a conversation about the genetic testing process and the subsequent test results with their child/children, barriers and/or facilitators to disclosure conversations, and the manner in which parents communicated the testing results.

Learning Objectives
  • Describe factors that influence when parents decide to initiate a conversation about genetic testing and the subsequent results.
  • Describe the barriers and facilitators parents identified in proceeding with testing and disclosure.
  • Identify the most common gram positive drug resistant organisms encountered in children with hematologic or oncologic disorders, and new pharmacologic therapies for managing drug resistant.
  • Describe the parental method of communication when disclosing results to their child/children.
  • Discuss implications for nursing practice.
Identified Learning Gap

As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • New and innovative therapies in hematology, oncology and hematopoietic progenitor cell transplant.
  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant
Learning Outcomes
  1. The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
  2. The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.

The measurement of these outcomes will be evidenced by evaluations and post testing.

Individual Learning Needs Assessment (ILNA) Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

Professional

CPHON® Blueprint

Professional

Faculty Disclosure of Relevant Financial Relationship(s)

Faculty and nurse planners report no conflict of interest with the content of this activity.

June

When is a Heavy Period More Than Just a Period? Finding Bleeding Disorders

Date: Tuesday, June 6, 2017
Time: 1 pm Central Time

Presenters

Kelly Tickle, MSN APN PCNS-BC CWON PPCNP-BC
Pediatric Nurse Practitioner
Children's Healthcare of Atlanta
Atlanta, GA

Robert F. Sidonio, MD MSc.
Associate Director of Hemostasis and Thrombosis
Emory University/Children's Healthcare of Wisconsin
Wauwatosa, WI

Description

Heavy menstrual bleeding is a common symptom in pubescent girls. It is often difficult for healthcare professionals to determine when the bleeding is related to a medical condition or attributable to an inherited bleeding disorder. Furthermore, heavy menstrual bleeding is quite prevalent in adolescent girls with inherited bleeding disorders such as von Willebrand disease, platelet function disorders and rare bleeding disorders ranging from 32-95%. Identifying these common bleeding disorders could help in optimizing medical management. In recent years, professionals from obstetrics, gynecology and hematology have developed guidelines for the evaluation and management of heavy menstrual bleeding in patients with bleeding disorders focused mostly on women. The recommendations provide a comprehensive guide in treating this medical condition in young women and help medical professionals to determine when a heavy period is more than just a heavy period. An algorithm is now available to help navigate the process.

Learning Objectives
  • Differentiate between normal menses and dysfunctional uterine bleeding.
  • Identify techniques to quantify heavy menstruation.
  • Identify the prevelance of hemostatic disorders in relation to menorrhagia.
  • Evaluate diagnostic tools to identify an inherited bleeding disorder.
  • Discuss treatment modalities for patients with inherited bleeding disorders and heavy menstruation.
Identified Learning Gaps  

 As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • Adolescent and young adult (AYA) issues
  • Pharmacotherapy
  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant
Learning Outcomes
  1. The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
  2. The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.

The measurement of these outcomes will be evidenced by evaluations and post testing.

Individual Learning Needs Assessment (ILNA) Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

Disease Related Biology

Pharmacology Content

This session is eligible for 0.17 pharmacology contact hours.

Faculty Disclosure of Relevant Financial Relationship(s)

Faculty and nurse planners report no conflict of interest with the content of this activity.

October

AALL1131Blinatumomab in First Relapse of B Lineage Acute Lymphoblastic Leukemia

Date:Thursday, October 12, 2017

Time:1 pm Central Time

Presenters

Sue Zupanec, RN NP
Nurse Practitioner
The Hospital for Sick Children
Toronto, ON Canada

Debra Schissel, RN CPON®
Lead Nurse Research Coordinator
Children's Hospital Colorado
Aurora, CO

Description

Current survival rates for most pediatric patients with a first relapse of acute lymphoblastic leukemia (ALL) are dismal. Treatment strategies for relapsed ALL include intensive chemotherapy often followed by hematopoietic stem cell transplant. Blinatumomab is a new targeted therapy that has shown promising clinical activity in early phase clinical trials in both adult and pediatric patients with relapsed ALL. Blinatumomab is a bispecific T-cell engager linking CD19 positive B-cells, including ALL cells, with CD3 T-cells, inducing T-cell activation and apoptosis. Blinatumomab has a distinctive toxicity profile including cytokine release syndrome (CRS) and reversible neurotoxicity. The current COG AALL1331 study aims to determine if the addition of Blinatumomab will improve outcomes for pediatric patients with a first relapse of ALL. This session will review the COG AALL1331 protocol and will include discussion of Blinatumomab administration and highlight nursing care of patients enrolled on this trial.

Learning Objectives
  • Review the background of pediatric relapsed ALL, including, risk classification, survival rates, and the most promising clinical trial results to date.
  • Describe the mechanism of action of Blinatumomab and review clinical activity and reported toxicity from early phase clinical trials both in adult and pediatric patients.
  • Review the COG AALL1331 protocol and the nursing considerations important for Blinatumomab administration and for the provision of nursing care for patients receiving this new targeted agent.
Identified Learning Gap

As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • New and innovative therapies in hematology, oncology and hematopoietic progenitor cell transplant.
  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant.
  • Pharmacotherapy
Learning Outcomes
  1. The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
  2. The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.

The measurement of these outcomes will be evidenced by evaluations and post testing.

Individual Learning Needs Assessment (ILNA) Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

Treatment

Pharmacology Content

This session is eligible for 0.25 pharmacology contact hours.

Faculty Disclosure of Relevant Financial Relationship(s)

Faculty and nurse planners report no conflict of interest with the content of this activity.

December

Leading at the Bedside: Do Families Trust you?

Date:December 14, 2017
Time:1 pm Central Time

Presenters

Kaye Schmidt, MA RN NEA-BC CPON®
Senior Director of the Center for Cancer & Blood Disorders
Children's Health, Children's Medical Center Dallas
Dallas, TX

Description

This session will discuss ways that direct caregivers can serve as leaders. In today's environment, where everyone is challenged with increasing efficiency, providing high quality care, and keeping up with the constant changes, nurses are challenged to function at a higher level. Coming to work and just doing your job no longer seems to be enough. Nurses are asked to participate in extra projects and committees, advance their education and/or obtain certification, be a team player, make sure patients and families are happy with their care, and maintain a positive attitude. Patients and families have high expectations and expect to be involved in their care. Recognizing how you, as a direct care nurse, can function as a leader may be enhanced by understanding the concept of trust, both in how you trust others, and in how patients and families form a trusting relationship with you and all caregivers.

Learning Objectives
  • Define ways that nurses in direct patient care roles can serve as leaders.
  • Examine the concept of trust and how it impacts your interactions with patients, families, co-workers and your boss.
  • Identify the 7 steps for healing from the Reina Trust Model. Apply them to a workplace relationship and a patient/family relationship.
Identified Learning Gap

As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:

  • Current trends in hematology/oncology and hematopoietic progenitor cell transplant
  • Effective self-care strategy
Learning Outcomes
  1. The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
  2. The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.

The measurement of these outcomes will be evidenced by evaluations and post testing.

Individual Learning Needs Assessment (ILNA) Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

CPHON® Blueprint

Professional

BMTCN® Blueprint
Faculty Disclosure of Relevant Financial Relationship(s)

Faculty and nurse planners report no conflict of interest with the content of this activity.

Webinar Archives

APHON members have access to archive recordings of past webinars. Continuing education credits may be earned for an additional fee after listening to the program content and completing a posttest and evaluation.

View list of archived webinars

Accreditation and Disclaimers

ONCC Official Statement and Disclaimer

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. More information is available on each individual webinar.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Accreditation Statement

The Association of Pediatric Hematology/Oncology Nurses (APHON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Pharmacology Content

Individual APHON webinars may be recognized for pharmacology content as calculated by the APHON Webinar Committee. APHON recommends that attendees retain a copy of webinar marketing materials for supportive documentation. Please note that you may not apply CNE toward pharmacology content. The content may be applied in only one area, nursing contact hours or pharmacology content.

Disclosure

A staff member, volunteer (faculty), or their family member who has an affiliation with a commercial company must declare that relationship in advance of involvement with an education activity that could be used as a forum to promote the interest of that company and its products. The material presented in this activity represents the opinion of the presenters and not necessarily the views of APHON. If there are any disclosures to report, they will be indicated in the individual activity.